Ascletis Pharma Inc.
1672.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.29B
Close$
Share Statistics
| Market cap | $7.29 Billion |
|---|---|
| Enterprise Value | $6.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.37 |
| Beta | 0.43 |
| Outstanding Shares | 1,039,794,415 |
Return
| Return on Equity | -37.24% |
|---|---|
| Return on Assets | -34.49% |
| Return on Invested Capital | -47.60% |
Valuation & Multiples
| P/E Ratio | -10.04 |
|---|---|
| PEG | -3.81 |
| Price to Sales | - |
| Price to Book Ratio | 3.48 |
| Enterprise Value to Revenue | 2034.66 |
| Enterprise Value to EBIT | -6.19 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$31.57 M
Average shareholder expectationNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
$48.54 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ascletis Pharma Inc.
202 employees
CEO: Jinzi J. Wu Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEV...